Fatty Acid Amide Hydrolase Inhib

Confirm delete?

Fatty Acid Amide Hydrolase Inhibitor Screening Assay Kit

Zoom

Cat No: 10005196

Assay Kits - Fluorometric Assays

The endocannabinoid system is a ubiquitous lipid signaling system involved in various regulatory functions throughout the body. The primary endocannabinoids, arachidonoylethanolamide (AEA) and 2-arachidonoyl glycerol (2-AG), are released upon demand f...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Correlated keywords:

fatty acid amide hydrolase anandamide amidohydrolase oleamide hydrolase endocannabinoid pain obesity neurological CB CB1 CB2 FAAH1

Product Overview:
The endocannabinoid system is a ubiquitous lipid signaling system involved in various regulatory functions throughout the body. The primary endocannabinoids, arachidonoylethanolamide (AEA) and 2-arachidonoyl glycerol (2-AG), are released upon demand from lipid precursors and bind to cannabinoid (CB1) receptors in the brain or CB2 receptors in the peripheral tissues. Fatty acid amide hydrolase (FAAH) is a cytosolic serine hydrolase responsible for the degradation of fatty acid amides, including AEA. Finding inhibitors to FAAH could offer a beneficial approach toward the treatment of pain, obesity, and various neurological diseases where higher endocannabinoid activity would be beneficial. Cayman’s FAAH Inhibitor Screening Assay Kit provides a convenient fluorescence-based method for screening FAAH inhibitors. FAAH hydrolyzes AMC-arachidonoyl amide resulting in the release of the fluorescent product, 7-amino-4-methylcoumarin (AMC). The fluorophore can be easily analyzed using an excitation wavelength of 340-360 nm and an emission wavelength of 450-465 nm.

Size	96 wells
Shipping	dry ice
Custom Code	3822.19
UNSPSC code	41116104

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.